-
公开(公告)号:US10669279B2
公开(公告)日:2020-06-02
申请号:US16455020
申请日:2019-06-27
Applicant: Pfizer Inc.
Inventor: Thomas Allen Chappie , Nandini Chaturbhai Patel , Matthew Merrill Hayward , Christopher John Helal , Simone Sciabola , Erik Alphie LaChapelle , Joseph Michael Young , Patrick Robert Verhoest
IPC: C07D487/04 , C07D519/00
Abstract: The present invention is directed to compounds of Formula I: or a pharmaceutically acceptable salt thereof, wherein the substituents R1, R3, R6, R7, and b are as defined herein. The invention is also directed to pharmaceutical compositions comprising the compounds, methods of treatment using the compounds, and methods of preparing the compounds.
-
公开(公告)号:US09598421B2
公开(公告)日:2017-03-21
申请号:US14817606
申请日:2015-08-04
Applicant: Pfizer Inc.
Inventor: Thomas Allen Chappie , Patrick Robert Verhoest , Nandini Chaturbhai Patel , Matthew Merrill Hayward , Christopher John Helal , Simone Sciabola , Erik Alphie LaChapelle , Joseph Michael Young
IPC: C07D487/04 , C07D519/00
CPC classification number: C07D487/04 , C07D519/00
Abstract: The present invention is directed to compounds of Formula I: or a pharmaceutically acceptable salt thereof, wherein the substituents R1, R3, R6, R7, and b are as defined herein. The invention is also directed to pharmaceutical compositions comprising the compounds, methods of treatment using the compounds, and methods of preparing the compounds.
-
公开(公告)号:US10590128B2
公开(公告)日:2020-03-17
申请号:US16069585
申请日:2017-01-09
Applicant: Pfizer Inc.
Inventor: Thomas Allen Chappie , Jaclyn Louise Henderson , Joseph Michael Young , Travis T. Wager , Bethany Lyn Kormos , Nandini Chaturbhai Patel , Simone Sciabola , Jamison Bryce Tuttle , Patrick Robert Verhoest , Joseph Walter Tucker
Abstract: The present invention provides compounds of Formula (I): and pharmaceutically acceptable salts thereof wherein the variables R1, R2, R3, R4, R5, a and A are as defined herein; processes for the preparation of; intermediates used in the preparation of; and compositions containing such compounds or salts, and their uses for treating D3-mediated (or D3-associated) disorders including, e.g., substance addiction, substance abuse, schizophrenia (e.g., its cognitive symptoms), cognitive impairment (e.g., cognitive impairment associated with schizophrenia, AD or PD), Parkinson's disease, mania, anxiety, impulse control disorders, sexual disorders and depression.
-
公开(公告)号:US20190047997A1
公开(公告)日:2019-02-14
申请号:US16069585
申请日:2017-01-09
Applicant: Pfizer Inc.
Inventor: Thomas Allen Chappie , Jaclyn Louise Henderson , Joseph Michael Young , Travis T. Wager , Bethany Lyn Kormos , Nandini Chaturbhai Patel , Simone Sciabola , Jamison Bryce Tuttle , Patrick Robert Verhoest , Joseph Walter Tucker
IPC: C07D471/04
Abstract: The present invention provides compounds of Formula (I): and pharmaceutically acceptable salts thereof wherein the variables R1, R2, R3, R4, R5, a and A are as defined herein; processes for the preparation of; intermediates used in the preparation of; and compositions containing such compounds or salts, and their uses for treating D3-mediated (or D3-associated) disorders including, e.g., substance addiction, substance abuse, schizophrenia (e.g., its cognitive symptoms), cognitive impairment (e.g., cognitive impairment associated with schizophrenia, AD or PD), Parkinson's disease, mania, anxiety, impulse control disorders, sexual disorders and depression.
-
公开(公告)号:US10077269B2
公开(公告)日:2018-09-18
申请号:US15426423
申请日:2017-02-07
Applicant: Pfizer Inc.
Inventor: Thomas Allen Chappie , Nandini Chaturbhai Patel , Matthew Merrill Hayward , Christopher John Helal , Simone Sciabola , Erik Alphie LaChapelle , Joseph Michael Young , Patrick Robert Verhoest
IPC: C07D487/04 , C07D519/00
CPC classification number: C07D487/04 , C07D519/00
Abstract: The present invention is directed to compounds of Formula I: or a pharmaceutically acceptable salt thereof, wherein the substituents R1, R3, R6, R7, and b are as defined herein. The invention is also directed to pharmaceutical compositions comprising the compounds, methods of treatment using the compounds, and methods of preparing the compounds.
-
公开(公告)号:US10131669B2
公开(公告)日:2018-11-20
申请号:US15327814
申请日:2015-07-10
Applicant: Pfizer Inc.
Inventor: Thomas Allen Chappie , Patrick Robert Verhoest , Nandini Chaturbhai Patel , Matthew Merrill Hayward , Christopher John Helal , Simone Sciabola , Travis T. Wager , Erik Alphie LaChapelle , Joseph Michael Young
IPC: C07D487/04 , A61K31/519
Abstract: The present invention is directed to pyrazolopyrimine compounds or pharmaceutically acceptable salts which are inhibitors of PDE4 isozymes, especially with a binding affinity for PDE4B isoform, and compositions thereof.
-
公开(公告)号:US20170204099A1
公开(公告)日:2017-07-20
申请号:US15327814
申请日:2015-07-10
Applicant: Pfizer Inc.
Inventor: Thomas Allen Chappie , Patrick Robert Verhoest , Nandini Chaturbhai Patel , Matthew Merrill Hayward , Christopher John Helal , Simone Sciabola , Travis T. Wager , Erik Alphie LaChapelle , Joseph Michael Young
IPC: C07D487/04
CPC classification number: C07D487/04
Abstract: The present invention is directed to compounds of Formula I: or a pharmaceutically acceptable salt thereof, wherein the substituents A, R1, R3, and b are as defined herein. The inventions also directed to pharmaceutical compositions comprising the compounds, methods of treatment using the compounds and methods of preparing the compounds.
-
公开(公告)号:US20200157098A1
公开(公告)日:2020-05-21
申请号:US16750505
申请日:2020-01-23
Applicant: PFIZER INC.
Inventor: Thomas Allen Chappie , Jaclyn Louise Henderson , Joseph Michael Young , Travis T. Wager , Bethany Lyn Kormos , Nandini Chaturbhai Patel , Simone Sciabola , Jamison Bryce Tuttle , Patrick Robert Verhoest , Joseph Walter Tucker
Abstract: The present invention provides compounds of Formula (I): and pharmaceutically acceptable salts thereof wherein the variables R1, R2, R3, R4, R5, a and A are as defined herein; processes for the preparation of; intermediates used in the preparation of; and compositions containing such compounds or salts, and their uses for treating D3-mediated (or D3-associated) disorders including, e.g., substance addiction, substance abuse, schizophrenia (e.g., its cognitive symptoms), cognitive impairment (e.g., cognitive impairment associated with schizophrenia, AD or PD), Parkinson's disease, mania, anxiety, impulse control disorders, sexual disorders and depression.
-
公开(公告)号:US20190322674A1
公开(公告)日:2019-10-24
申请号:US16455020
申请日:2019-06-27
Applicant: Pfizer Inc.
Inventor: Thomas Allen Chappie , Nandini Chaturbhai Patel , Matthew Merrill Hayward , Christopher John Helal , Simone Sciabola , Erik Alphie LaChapelle , Joseph Michael Young , Patrick Robert Verhoest
IPC: C07D487/04 , C07D519/00
Abstract: The present invention is directed to compounds of Formula I: or a pharmaceutically acceptable salt thereof, wherein the substituents R1, R3, R6, R7, and b are as defined herein. The invention is also directed to pharmaceutical compositions comprising the compounds, methods of treatment using the compounds, and methods of preparing the compounds.
-
公开(公告)号:US20180346475A1
公开(公告)日:2018-12-06
申请号:US16056968
申请日:2018-08-07
Applicant: Pfizer Inc.
Inventor: Thomas Allen Chappie , Nandini Chaturbhai Patel , Matthew Merrill Hayward , Christopher John Helal , Simone Sciabola , Erik Alphie LaChapelle , Joseph Michael Young , Patrick Robert Verhoest
IPC: C07D487/04 , C07D519/00
CPC classification number: C07D487/04 , C07D519/00
Abstract: The present invention is directed to compounds of Formula I: or a pharmaceutically acceptable salt thereof, wherein the substituents R1, R3, R6, R7, and b are as defined herein. The invention is also directed to pharmaceutical compositions comprising the compounds, methods of treatment using the compounds, and methods of preparing the compounds.
-
-
-
-
-
-
-
-
-